Overview

Metformin Experience on Minimal Hepatic Encephalopathy

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
All
Summary
Primary aim: -To assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. Secondary aim: -To evaluate if metformin is a safety drug in patients showing liver cirrhosis.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Treatments:
Metformin
Criteria
Inclusion Criteria:

- Patients with > 18 years old

- Patients with the results of all the factors evaluable at the time of inclusion

- Patients who have accepted their participation in the study through informed consent

- Patients showing liver cirrhosis by ultrasound, transient elastography or liver biopsy

- Patients showing minimal hepatic encephalopathy (PHES < 4 or Critical Flicker
Frequency < 39 Hz)

Exclusion Criteria:

- Patients with any contraindications to the drugs used

- Patients showing type 1 diabetes mellitus

- Patients showing type 2 diabetes mellitus and previous or current use of exogenous
insulin, metformin or other oral antidiabetic drug